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SPECIAL ARTICLENew Insulin Delivery Recommendations
Anders H. Frid, MD; Gillian Kreugel, DSN; Giorgio Grassi, MD; Serge Halimi, MD;
Debbie Hicks, DSN; Laurence J. Hirsch, MD; Mike J. Smith, DSN;
Regine Wellhoener, MD; Bruce W. Bode, MD; Irl B. Hirsch, MD; Sanjay Kalra, MD;
Linong Ji, MD; and Kenneth W. Strauss, MDAbstract
Many primary care professionals manage injection or infusion therapies in patients with diabetes. Few
published guidelines have been available to help such professionals and their patients manage these ther-
apies. Herein, we present new, practical, and comprehensive recommendations for diabetes injections and
infusions. These recommendations were informed by a large international survey of current practice and
were written and vetted by 183 diabetes experts from 54 countries at the Forum for Injection Technique and
Therapy: Expert Recommendations (FITTER) workshop held in Rome, Italy, in 2015. Recommendations
are organized around the themes of anatomy, physiology, pathology, psychology, and technology. Key
among the recommendations are that the shortest needles (currently the 4-mm pen and 6-mm syringe
needles) are safe, effective, and less painful and should be the first-line choice in all patient categories;
intramuscular injections should be avoided, especially with long-acting insulins, because severe hypogly-
cemia may result; lipohypertrophy is a frequent complication of therapy that distorts insulin absorption,
and, therefore, injections and infusions should not be given into these lesions and correct site rotation will
help prevent them; effective long-term therapy with insulin is critically dependent on addressing psycho-
logical hurdles upstream, even before insulin has been started; inappropriate disposal of used sharps poses a
risk of infection with blood-borne pathogens; and mitigation is possible with proper training, effective
disposal strategies, and the use of safety devices. Adherence to these new recommendations should lead to
more effective therapies, improved outcomes, and lower costs for patients with diabetes.
ª 2016 Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://
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the end of this article.C orrect technique in insulin delivery iscritical for optimal control of dia-betes. This article reviews the most
recent studies in the field and then offers
new injection and infusion recommendations
for insulin users. It is meant to complement
and extend the injection recommendations
published in 2010.1 These latest recommenda-
tions were based on the results of the fourth
Injection Technique Questionnaire (ITQ) sur-
vey (published elsewhere in this issue). From
February 2014 through June 2015, 13,289
insulin-injecting patients with diabetes from
42 countries participated in the ITQ survey,
one of the largest multinational studies of its
kind. A smaller Infusion Technique Question-
naire survey was undertaken concurrently
with the ITQ in 356 patients using continuous
subcutaneous insulin infusion (CSII) in four
countries and informed the drafting of the
new infusion recommendations.Mayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.org n ª 2016 Mayo Foundation for Me
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The ITQ survey results (for injection and
infusion) and the initial draft of these recom-
mendations were presented at the Forum for
Injection Technique and Therapy: Expert Rec-
ommendations (FITTER) workshop held in
Rome, Italy, on October 23 and 24, 2015, at
which 183 physicians, nurses, educators, and
allied health care professionals (HCPs) from
54 countries (see the list in Supplemental Ap-
pendix 1, available online at http://www.
mayoclinicproceedings.org)2 met to debate,
revise, and adapt these proposals. FITTER
was the fourth in a series of expert workshops
that have issued recommendations on insulin
delivery.1,3-5
MATERIALS AND METHODS
Publications were identified using Medline,
EMBASE, PubMed, and Cochrane Controlled
Trials. The search was focused on the period
between January 2008 and December 2015,.org/10.1016/j.mayocp.2016.06.010
dical Education and Research. This is an open access article under the CC BY-NC-ND
1231
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1232although we had at our disposal the medical
literature going back to 1980. We used the
terms subcutaneous injections, insulin, injection
technique, insulin infusion, CSII sets, infusion
sets, and glucagon-like peptide-1 receptor ago-
nists (GLP-1). For those seeking other related
terms, a glossary is also available as Supple-
mental Appendix 2 (available online at http://
www.mayoclinicproceedings.org).2 Of 368 ar-
ticles found, 254 met the criteria for inclusion
as outlined in the Cochrane Handbook for
Systematic Reviews of Interventions.6
One of us (K.W.S.) drafted the initial
version of the recommendations. This draft
was then extensively revised during 12
monthly web conferences with a group of in-
ternational experts in injection and infusion
techniques (see authors). This new draft was
then extensively revised by the 183 expert in-
vitees to the FITTER meeting in Rome. After
FITTER, additional revisions were made by
FITTER attendees. The current version reflects
the collective input of these diabetes experts
from around the world and bears little resem-
blance to the earlier drafts.
The panel used a previously established
scale1,4,7 for the strength of each recommenda-
tion: A ¼ strongly recommended, B ¼ recom-
mended, and C ¼ unresolved issue. For
grading the degree of scientific support for
each recommendation, we used the following
scale: 1¼ at least 1 rigorously performed study
that is peer reviewed and published (excludes
observational studies); 2 ¼ at least 1 observa-
tional, epidemiologic, or population-based
published study; and 3 ¼ expert consensus
opinion informed by broad patient experience.
This simplified version of the grading scales
commonly used7 was believed to be more
appropriate for our field, where randomized,
controlled outcome trials are rarely available
but good-quality studies on the performance
of devices do exist. Each recommendation is
followed by a letter and number in bold (eg,
A2). The letter indicates the importance that
the recommendation should have in practice,
and the number indicates its level of evidence
in the medical literature. The most relevant
publications bearing on a recommendation
are also cited or summarized. Although these
recommendations will be suitable for most pa-
tients, individual exceptions may occur for
which the guidelines should be adapted.Mayo Clin Proc. n September 2016;91ANATOMY
Skin Thickness
The skin is the first obstacle a needle must tra-
verse when giving an injection or infusion. A
variety of studies of adult skin at injection sites
using various imaging techniques have all
shown similar results: the skin varies in thick-
ness from approximately 1.25 to 3.25 mm in
90% of individuals and averages approximately
2.0 to 2.5 mm. Studies have included both
healthy volunteers and persons with diabetes,
and their results are consistent across age
groups, sexes, body mass indexes (BMIs), and
geographic locations. Studies included four
ethnic groups in the United States8; Italian9
and South African10 children and adolescents
with type 1 diabetes; and groups of Chinese,11
Indian,12 Filipino,13 and Korean adults14 (most
with type 2 diabetes). Details of these studies
are summarized in Supplemental Figure 18
and Supplemental Tables 1-4 (available online
at http://www.mayoclinicproceedings.org).9-15
The skin is slightly less thick in children,
but by puberty it increases to adult levels.
However, these differences are small and are
irrelevant for insulin injections and infusions.
In both children and adults, even the shortest
needles (4 mm) reliably traverse the skin and
enter the subcutaneous (SC) fat.SC Thickness
The distance from the surface of the skin to
the muscle fascia (ie, the sum of skin and SC
thickness) determines the potential for intra-
muscular (IM) injection. Compared with skin
thickness, which is relatively constant, SC
tissue thickness varies widely. Ultrasound
measurements of skin and SC thickness at in-
sulin injection sites in adult patients with dia-
betes have recently been published.11,13 See
Supplemental Tables 1-49-15 for a summary
of findings from the most important of these
studies. Gibney et al8 and Hirsch et al15 (sepa-
rate reports on the same study) measured SC
fat depth at single locations in the thigh,
arm, abdomen, and buttock. Studies by
Ludescher et al16 and Sim et al14 (where 8-
10 measurements were taken and averaged
for each body site) largely confirmed the ultra-
sound study findings from a single site.
Several rules of thumb have emerged from
these studies: SC fat thickness increases in(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
www.mayoclinicproceedings.org
NEW INSULIN DELIVERY RECOMMENDATIONSdirect proportion to BMI; women, on average,
have an approximately 5-mm greater SC fat
thickness than men at the same BMI; and trun-
cal sites (abdomen and buttocks) have thicker
SC fat layers than limbs (thighs and arms) in
the same individual. The most important
outcome of these studies is that they inform
us about the risk of IM injections. Intramus-
cular deposition of insulin leads to unpredict-
able (largely faster) absorption of insulin and
destabilization of the blood glucose level. Intra-
muscular injections occur more frequently with
longer needles, in slimmer and younger pa-
tients, males, and in those who use limbs rather
than truncal sites for insulin delivery.
Supplemental Tables 5-98,11,14,15 (available
online at http://www.mayoclinicproceedings.
org) provide estimates of the IM injection risk
by site, needle length, and patient type.
Different risk estimates in several studies reflect
differing patient populations with a wide range
of average BMIs.
Children aged 0 to 2 years have higher
BMIs and more SC tissue than preschool chil-
dren. Preschool children (2-6 years old) are
usually at the thinnest point in their lives, and
both sexes usually have very little SC tissue.
School-age children (7-13 years old) slowly
gain SC tissue, but there are few sex differences
until puberty. During puberty, young women
gain considerably more SC tissue than young
men owing to hormonal influences. See Sup-
plemental Tables 1-49-15 for a summary of find-
ings from the most important pediatric studies.
See Supplemental Table 109,10 (available online
at http://www.mayoclinicproceedings.org) for
estimates of IM risk in pediatric patients by
site, needle length, and patient age.PHYSIOLOGY
Risk of IM Injections
Insulin absorption rates from IM injections differ
according to the activity of the muscle. Muscle
canbe resting (eg, abdominalmuscles in a recum-
bent person), active (abdominal muscles in a
standing person), or exercising (abdominal mus-
cles in a person doing sit-ups). Intramuscular-
injected insulin is absorbed differently in resting,
active, and exercising muscle, with the rate
increasing as one progresses through the 3 stages.
Human insulins and analogues have
different absorption profiles when depositedMayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orginto muscle. Intramuscular injections, espe-
cially into working muscle, can distort absorp-
tion and, thus, decouple maximum blood
glucose levels from peak insulin activity. This
can cause poor glycemic control, including
excessive glycemic variability. Intramuscular
injections can lead to frequent and unexplained
hypoglycemia according to several studies.17-19
Patientsmay be unaware that they are inject-
ing IM. Several clinical pointers can give clues
as to whether the injection is IM or SC. Intra-
muscular injections can lead to a greater risk of
bleeding, bruising, and pain. The pain may be
described as stinging, and it worsens if the rele-
vantmuscle is contractedwith the needle in situ.
If a patient releases the syringe with the needle
still under the skin, it may continue to stand
upright if it is IM (whereas it topples over in
SC injections).20 Unexplained glycemic vari-
ability and episodes of hypoglycemia may sug-
gest IM injection. At special risk are children,
thin persons, and persons using longer needles
or following improper technique.
Needle Length
The needle lengths that were once recommen-
ded for SC injection (for adults, 8 mm; for
children, 6 mm) are now known to be too
long because they increase the risk of IM injec-
tions without evidence of improved glucose
control.21-23 Shorter needles are much safer
and are better tolerated and less painful. Hirsch
et al24 compared a 4-mm pen needle with 5-
and 8-mm needles in a large randomized
controlled study. The 4-mm needle was shown
to be safe and efficacious in adult patients of all
sizes (ie, equivalent glucose control); skin
leakage was equivalent and pain scores were
improved with the 4-mm needle. Similar
studies have been performed in various other
groups,25-27 including obese patients.28 All
earlier studies on needle length29-37 have also
shown similar glucose control (glycated hemo-
globin, glycated albumin, or fructosamine)
without increased leakage with the shorter-
length needle. The shortest-length pen needle
is 4 mm, but the shortest syringe needle
today is 6 mm long (the syringe needle has to
pass through the vial septum or stopper).
Insulin pharmacokinetics/pharmacodynamics
has been shown to be the same when injected
into resting individuals using short and long
needles.27,38,39 A summary of these needle.org/10.1016/j.mayocp.2016.06.010 1233
MAYO CLINIC PROCEEDINGS
1234length and insulin absorption studies is pre-
sented in Supplemental Appendix 3 (available
online at http://www.mayoclinicproceedings.
org).32,36,40-70Recommendations.
d The 4-mm needle is long enough to traverse
the skin and enter the SC tissue, with little
risk of IM (or intradermal) injection. There-
fore, it is considered the safest pen needle
for adults and children regardless of age,
sex, ethnicity, or BMI. A1
d The 4-mm needle may be used safely and
effectively in all obese patients. Although it
is the needle of choice for these patients, a
5-mm needle may also be acceptable. A1
d The 4-mm needle should be inserted
perpendicular to the skin (at 90 to the
skin surface), not at an angle, regardless of
whether a skinfold is raised. A1
d Very young children (6 years old) and
very thin adults should use the 4-mm needle
by lifting a skinfold and inserting the needle
perpendicularly into it. Others may inject
using the 4-mm needle without lifting a
skinfold. A1
d The safest currently available syringeneedle for
all patients is 6 mm in length. However, when
any syringe needle is used in children (6
years old), adolescents, or slim to normal-
weight adults (BMI of 19-25 [calculated as
the weight in kilograms divided by the height
in meters squared]), injections should always
be given into a lifted skinfold. A1
d Use of syringe needles in very young children
(<6 years old) and extremely thin adults
(BMI <19) is not recommended, even if
they use a raised skinfold, because of the
excessively high risk of IM injections. A1
d Health care authorities and payers should be
alerted to the risks associated with using sy-
ringe or pen needles 6 mm or longer in chil-
dren. A2
d Children still using the 5-mm pen needle
should inject using a lifted skinfold. Chil-
dren using pen needles 5 mm or longer
should be switched to 4-mm pen needles
if possible and if not should always use a
lifted skinfold. A2
d Injecting at a 45 angle using a 6-mm needle
is an acceptable substitute for lifting a skin-
fold because the net penetration of a 45Mayo Clin Proc. n September 2016;91injection using the 6-mm needle is approxi-
mately 4 mm.71 A1
d If arms are used for injections with needles 6
mm or longer, a skinfold must be lifted. This
requires that the injection be given by a
third party. A2
d Avoid pushing the needle hub in so deeply
that it indents the skin because this increases
the risk of IM injections. B3
d Patients with tremors or other disorders that
make them unable to hold a 4-mm pen nee-
dle in place may need longer needles. B3
d High-flow needles (with extra-thin walls)
have been shown to be appropriate for all
injecting patients. Their obstruction, bending,
and breakage rates are the same as for conven-
tional-quality needles (extremely low) and
offer flow and ease-of-use advantages. A3Site Care
The recommended injection and infusion sites
are the abdomen, thigh, buttock, and upper
arm.72-76 Suggested boundaries in these sites
for insulin delivery are stated in the golden
rules (see the Appendix).
Recommendations.
n Patients should inspect the site before injec-
tion. Injections should be given into clean
sites, only using clean hands.77-79 A2
n If the site is found to be unclean it should be
disinfected. Disinfection is also required in
institutional settings such as hospitals and
nursing homes. If alcohol is used, it must
be allowed to dry completely before the in-
jection is given.80,81 A2
n Disinfection is usually not required when
injections are given in noninstitutional set-
tings such as homes, restaurants, and work-
places.82-86 A3
n Patients should never inject into sites of
lipohypertrophy (LH), inflammation, edema,
ulceration, or infection.84-92 A1
n Patients should not inject through clothing
because they cannot inspect the site before-
hand or easily lift a skinfold.80 B2Proper Use of Pens
When patients use pens they usually cannot
see the insulin going in as they can with a
syringe. Obstruction of insulin flow with(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
www.mayoclinicproceedings.org
NEW INSULIN DELIVERY RECOMMENDATIONSpens, although rare, can have serious conse-
quences. When teaching patients proper pen
use, HCPs should consult the instruction
manual for the specific device being used.
Several basic steps are important to follow
with any pen injector, but few of these are
known by (or taught to) patients. For example,
it is important not to accidentally push the
thumb button before the pen needle tip is
inserted in the SC tissue. In fact, it is best not
to touch the thumb button until the needle is
completely inserted. Once the thumb button
is pushed, patients should keep pressure on it
until the needle is completely withdrawn from
the body. If the button is released while the nee-
dle is still in the skin, body fluid and cells may
be aspirated into the cartridge and contaminate
it.93 Another important step is to always push
the button vertically (along the axis of the
pen). Some patients, especially the frail or
elderly, are unable to completely inject their to-
tal dose because they are pushing the button
obliquely, eg, by pushing on its edge, generating
excessive resistance along its glide path.94,95Recommendations.
n Pens should be primed before injections to
ensure free and unobstructed flow. Manu-
facturer’s instructions should be followed.
Priming entails seeing at least a drop of in-
sulin at the tip of the needle. Once free
flow is verified, the patient may dial the
desired dose and inject.96,97 A3
n Pens and their cartridges are for single-
person use only and should never be shared
among patients. Otherwise, biologic mate-
rial from one person can be drawn into
the cartridge and then injected into another
person.82,98 A2
n After use, needles should not be left
attached to the pen but rather disposed of
immediately. Otherwise, air or other con-
taminants can enter the cartridge or medica-
tion can leak out, both of which can distort
dose accuracy.45,99-103 A2
n Pen needles should be used only once. They
are no longer sterile after use.3,4,83,84,88,103-105
A2
n The thumb button should be touched only
after the pen needle is fully inserted. After
that, the button should be pressed along
the axis of the pen, not at an angle.99 A2Mayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orgn After the thumb button is completely pushed
in, patients should count slowly to 10 and
then withdraw the needle from the skin.
This is necessary to prevent medication
leakage and to get the full dose.45,105-108 A1
n Some patients may need to count past 10,
especially when giving higher doses. Count-
ing only to 5 may be acceptable for lower
doses. Patients may find the right time for
themselves by trial and error, using leakage
or dribbling of insulin as a guide. A3
n Pressure should be maintained on the
thumb button until the needle is withdrawn
from the skin to prevent aspiration of pa-
tient tissue into the cartridge.100,101 A2Proper Use of Syringes
Although insulin pens continue to grow in
popularity, there are still many regions of the
world where syringes are used extensively.
Each syringe has scale markings appropriate
for only one concentration of insulin, and mis-
matches of syringes to insulin can lead to
serious underdosing or overdosing. In some
countries, both U-40 and U-100 insulin may
be on the market together. In others, concen-
trations varying from U-100 to U-500 may
be simultaneously available. Patients should
avoid using syringes with detachable needles
because permanently attached needle syringes
deliver better dose accuracy, have far less dead
space, and allow the mixing of insulins if
needed. Currently, there are no syringes with
needles less than 6 mm in length because of
incompatibility with some vial stoppers.109
Recommendations.
d Syringe users should ensure that their device
is appropriate for the concentration of insu-
lin they are using. A3
d When drawing up insulin from a vial, the
user should first draw air into the syringe
at a dose equal to (or slightly greater than)
the dose of insulin to be given. This air is
then injected into the vial to facilitate with-
drawal of insulin. A3
d If air bubbles are found in the syringe, tap
on the barrel to bring them to the surface.
They may then be removed by pushing the
plunger up. A3
d With syringes, unlike pens, the needle does
not need to be left under the skin for a count.org/10.1016/j.mayocp.2016.06.010 1235
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1236of 10 after the plunger has been fully
depressed.105,106,110 A3
d Syringe needles should be used only
once. They are no longer sterile after
use.3,4,83,84,88,109,111,112 A2Insulin Analogues and Other Injectables
(GLP-1 Receptor Agonists)
Few studies address proper injection tech-
nique with these newer agents. Earlier studies
suggested that absorption rates of rapid-acting
analogues are similar between fat tissue and
resting muscle; absorption from working
muscle was not tested.111,112
Recommendations.
d Rapid-acting analogues can be given at any
of the injection sites. Rates of absorption
have not been shown to be site spe-
cific.113-115 A2
d Intramuscluar injection of rapid-acting
insulin analogues should be avoided if
possible.116 A2
d Similarly, long-acting analogues may also be
given at any of the injection sites. However,
IM injection should be scrupulously avoided
because it can lead to profound hypoglyce-
mia.115,117 B2
d Pending further studies, patients using non-
insulin injectable therapies (such as GLP-1
receptor agonists) should follow the estab-
lished recommendations for insulin injections
(regarding needle length, site selection, and
rotation).107,116 A2Human Insulins
Regular insulin (also known as soluble human
insulin) has a slower absorption rate than
rapid-acting analogues. Neutral protamine
Hagedorn (NPH) insulin and other older
long-acting insulins have absorption peaks
that can lead to hypoglycemia, especially
when given in larger doses.
Recommendations.
d It is preferable that NPH (when given alone)
be injected at bedtime rather than earlier in
the evening to reduce the risk of nocturnal
hypoglycemia. A1
d Intramuscular injections of NPH and other
long-acting insulins must be strictly avoidedMayo Clin Proc. n September 2016;91because of the risk of serious hypoglycemia
(Anders H. Frid, MD, oral communication,
October 24, 2015).17,117 A2
d The preferred site for regular (soluble human)
insulin is the abdomen because absorption of
this insulin is fastest there.21,38,118-120 A1
d The regular/NPH insulin mix should be
given in the abdomen to increase the speed
of absorption of the short-acting insulin to
cover postprandial glycemic excursions.18
A1
d If there is a risk of nocturnal hypoglycemia,
NPH and NPH-containing insulin mixes
given in the evening should be injected
into the buttock or thigh because these sites
have slower absorption rates for NPH insu-
lin.79,121,122 A1Lifting a Skinfold
Lifting a skinfold is required when the distance
from the skin surface to the muscle is less than
or equal to the needle length. Lifting a skinfold
in the abdomen nearly doubles the skin-to-
muscle distance. In the thigh, it is sometimes
difficult to lift a skinfold, and the mean in-
crease in skin-to-muscle distance may be
only 20%. In thin patients, thigh skinfolds
may actually decrease the distance to muscle
fasciadthe exact opposite of what is desired.42
Lifting a skinfold is rarely needed in the but-
tocks because of the abundance of SC tissue
there. When performed in the arm, skinfolds
must be lifted by someone other than the
patient.
Recommendations.
d A correct fold is made by lifting the skin
with the thumb and index finger (possibly
adding the middle finger). If the skin is lifted
using the whole hand, muscle may be lifted
as well as SC tissue, which can lead to IM in-
jections.123 A3
d Skinfolds should be lifted gently and not
squeezed so tightly as to cause blanching
or pain. A3
d The optimal sequence when injecting into a
skinfold is as follows: (1) gently lift a skin-
fold, (2) inject the insulin slowly at a 90
angle to the surface of the skinfold, (3) let
the needle remain in the skin for a count
of 10 after the plunger is depressed (when
using a pen), (4) withdraw the needle from(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
www.mayoclinicproceedings.org
NEW INSULIN DELIVERY RECOMMENDATIONSthe skin at the same angle it was inserted,
(5) release the skinfold, and (6) dispose of
the used needle safely. A3Cloudy Insulin Resuspension
Several studies have shown that cloudy
insulins are often inadequately resus-
pended.110,124-127 Crystals of insulin must be
mechanically agitated so that they go back
into solution before injection, but many pa-
tients do not know how to do this or do it
inappropriately. Inadequate resuspension can
lead to varying concentrations of insulin and
unpredictable clinical responses. A summary
of key studies on insulin resuspension can be




d Gently roll and tip cloudy insulins (eg, NPH
and premixed insulins) until the crystals are
resuspended (the solution becomes milk
white).110,124-129 A2
d Tipping involves one full up-down motion
of the pen or vial, and rolling is a full
rotation cycle between the palms. One
evidence-based method involves rolling the
insulin cartridge horizontally between the
palms 10 times for 5 seconds, then tipping
10 times for 10 seconds at room tempera-
ture.129 A2
d Visually confirm that the resuspended insu-
lin is sufficiently mixed after each rolling
and tipping, and repeat the procedure if
crystal mass remains in the cartridge. A2
d Vigorous shaking should be avoided
because this produces bubbles that will
affect accurate dosing. Avoid exposing insu-
lin to direct heat, light, or excessive agita-
tion. A2
d Store unopened insulin in a refrigerator in
which there is no risk of freezing. A2
d After initial use (in pen, cartridge, or vial),
insulin should be stored at ambient temper-
ature (15-30C or 59-86F) for up to 30
days or according to the manufacturer’s rec-
ommendations and within expiration dates.
Premixed insulin pens and some of the
newer insulins may vary in storage guide-
lines, so patients should check the manufac-
turer’s recommendations.129-131 A2Mayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orgd If room temperatures exceed 30C (86F),
then insulin in current use should be stored
in a refrigerator. It should be allowed to
warm up before injection. Insulin can be
warmed by rolling it between the palms. A2
Pregnancy
Studies are still lacking on the optimal inject-
ing technique during pregnancy, but the
following recommendations are considered
reasonable.
Recommendations.
d When fetal ultrasound is performed, SC fat
patterns in the mother may be assessed at
the same time and recommendations given
to her regarding safe zones for injections.132
B2
d The abdomen is generally a safe site for insu-
lin administration during pregnancy. Given
the thinning of abdominal fat from uterine
expansion, pregnant women with diabetes
(of any type) should use a 4-mm pen needle.
B2
d First trimester: Women should be reassured
that no change in insulin site or technique
is needed. B2
d Second trimester: Insulin can be injected over
the entire abdomen as long as properly
raised skinfolds are used. Lateral aspects of
the abdomen can be used to inject insulin
when no skinfold is raised. B2
d Third trimester: Injections can be given into
the lateral abdomen as long as they are
made into properly raised skinfolds. Appre-
hensive patients may use the thigh, upper
arm, or buttock instead of the abdomen. B2Role of the HCP
Currently there are 3 classes of injectable ther-
apies for diabetes: insulin, GLP-1 receptor
agonists, and amylin analogues.41,133,134 Of
these, only insulin is in common use for
CSII. Despite more than 90 years of use, insu-
lin injections and infusions are often per-
formed incorrectly, with adverse clinical
consequences for patients and additional costs
for payers. Often, even simple rules are not
taught or followed. The HCP has a crucial
role in the proper use of these therapies.
Proper technique is essential to achieve
optimal diabetes control, reduce variability,.org/10.1016/j.mayocp.2016.06.010 1237
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Often the most important determinant of pa-
tients’ injection technique is the knowledge
and commitment of their HCP.
Recommendations.
n Key tasks of the HCP include helping
patients (and caregivers) overcome the psy-
chological obstacles related to injecting or
infusing, especially at the initiation of treat-
ment, and then teaching them how to
perform the procedure correctly. A2
n The HCP must understand the anatomy and
physiology of insulin delivery sites so that
IM injections/infusions, LH, leakage, and
other complications are avoided. A2
n The HCP must understand the pharmaco-
kinetics of the therapeutic agents and the
absorption profiles of the various delivery
sites. A2Therapeutic Education
Decisions regarding insulin therapy should be
made jointly by the HCP and the patient (and
caregivers).137,138 Not all patients receive
appropriate education about injections/
infusions, and not all essential topics are
covered.139-141 Education in a group setting
may lead to better adherence and lower gly-
cated hemoglobin values if the HCP has
training as an educator.142 A summary of
studies on therapeutic education for insulin
delivery can be found in Supplemental Appen-
dix 5 (available online at http://www.
mayoclinicproceedings.org).143,144
Recommendations.
d Explore anxieties about insulin and the
injecting/infusing process.139,145 A3
d Discuss each of the essential topics (see the
next recommendation) at initiation of ther-
apy and at least once a year thereafter.
Make sure that information is delivered
verbally and in writing and has been fully
understood.146 A3
d Essential topics include the injecting/infusing
regimen; the choice and management of the
devices used; the choice, care, and self-
examination of injection sites; proper injection
techniques (timing, site rotation, injection
angle, skinfolds, insulin storage, resuspension
of cloudy insulin, etc); injection complicationsMayo Clin Proc. n September 2016;91and how to avoid them; optimal needle
lengths; safe disposal of used sharps; and psy-
chological hurdles and aids to overcome
them.137-139,143,146-149 A1
d Instructions should be given in verbal and
written form, and adherence should be
checked. To confirm adherence to prescrip-
tions, ask to see the needles, insulin, and
other devices from the latest batch received
from the pharmacy. A3
d Assess each injection/infusion site visually
and by palpation, if possible, at each visit
but at minimum once a year.139,143,150 A3PATHOLOGY
Lipohypertrophy
Lipodystrophy is a disorder of fat tissue. There are
2 main types of lipodystrophy: lipoatrophy,
which is loss of adipocytes that clinicallymanifests
as indenting and cratering, and LH, which is
enlargement of adipocytes that manifests as
swelling or induration of fat tissue.151 An even
rarer type of lipodystrophy is amyloidosis,152-155
for which a biopsy and pathologic diagnosis
are usually necessary. Insulin injected into
amyloiddepositsmayhave substantially impaired
absorption. Usually, LH regresses after stopping
insulin injections into the lesions, whereas local-
ized amyloidosis does not. Distinguishing these
lesions is clinically important.
Lipohypertrophy is common, although
studies vary on the exact frequency. A Spanish
study156 found LH in nearly two-thirds of
injecting patients (64.4%) (type 1 diabetes,
72.3% vs type 2 diabetes, 53.4%). An Italian
study143 found the prevalence to be 48.7%,
and in a Chinese study157 it was 53.1%. The
absorption of insulin injected into LH lesions
may be erratic and unpredictable, which can
lead to hyperglycemia, unexpected hypoglyce-
mia, or increased glucose variability.158,159
Conversely, patients who switch from injecting
into LH lesions to normal tissue are at risk for
hypoglycemia unless they lower their doses. A
summary of additional studies in LH and
pointers for optimizing the physical examina-
tion for LH are presented in Supplemental
Appendix 6 (available online at http://www.
mayoclinicproceedings.org) (Irl B. Hirsch,
MD, oral communication, October 24,
2015).88,160-177 Lipoatrophy studies are also
summarized at this site.(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
www.mayoclinicproceedings.org
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d Sites should be examined by the HCP for LH
at least once a year, or more frequently if LH
is already present. It is often easier to palpate
LH than to see it. Use of a lubricating gel
facilitates palpation.139,178 A2
d The physical examination for LH is ideally
performed with the patient lying down
and disrobed to the underwear. But in cir-
cumstances that preclude this, examination
of the patient sitting, standing, or partially
clothed is acceptable. A3
d Teach patients to inspect their own sites,
and give training in site rotation, proper in-
jection technique, and detection and pre-
vention of LH. A2
d After obtaining patient consent, make 2 ink
marks at the extreme edges of LH with a
single-use skin-safe marker. This will allow
the LH to be measured for future assess-
ment. If visible, the lesions could also be
photographed. A2
d Patients should be encouraged to avoid
injecting into areas of LH until the next ex-
amination by an HCP. Use of larger injection
zones, correct injection site rotation, and
non-reuse of needles should be recommen-
ded.179,180 A2
d Switching injections away from LH and to
normal tissue often requires a decrease in
the dose of insulin injected. The amount
of decrease varies from one individual to
another and should be guided by blood
glucose measurements. Reductions often
exceed 20% of their original dose.87 A1Rotation of Injection Sites
A variety of studies have shown that the best
way to safeguard normal tissue is to consis-
tently and properly rotate injection sites.181,182
Injection can be rotated from one body region
to another (abdomen to thigh, to buttock, to
arm), but note that absorption characteristics
change depending on the type of insulin given.
Analogues may be given at any injection site
with similar uptake and action (pharmacoki-
netics/pharmacodynamics), but human insu-
lins (regular, NPH) vary substantially, with
absorption being fastest from the abdomen
and slowest from the buttocks. Correct rotation
involves spacing injections a least 1 cm
(approximately the width of an adult finger)Mayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orgapart even within an injection zone. Additional
study summaries on rotation are presented in
Supplemental Appendix 7 (available online at
http://www.mayoclinicproceedings.org).2
Recommendations.
d Injections should be systematically rotated
to avoid LH. This means injecting at least
1 cm (or approximately the width of an
adult finger) from previous injections, a vital
procedure that requires careful planning and
attention. A2
d Patients should be given an easy-to-follow
rotation scheme from the beginning of
injection/infusion therapy. The HCP should
review the site rotation scheme with the
patient at least once a year.182-188 A2
d One evidence-based scheme involves
dividing injection sites into quadrants (or
halves when using the thighs or buttocks),
using one quadrant per week, and rotating
quadrant to quadrant in a consistent direc-
tion (eg, clockwise) (scheme courtesy of
Lourdes Saez-de Ibarra and Ruth Gaspar,
diabetes nurses and specialist educators at
La Paz Hospital, Madrid, Spain). A3Needle Reuse
Many insulin injectors find it burdensome to
carry extra needles when away from home.
They also are reluctant to carry containers to
dispose of used needles. Sometimes patients
have to pay a portion or the entire cost of their
needles, and some decide that it is not worth it
to buy a new needle for each injection. Others
find that the injections from reused needles are
not noticeably more painful, as long as they do
not reuse excessively. Finally, some patients
believe that disposing of a needle after 1 use
is ecologically wasteful because the metal and
plastic must be incinerated.
However, official labeling on needles re-
quires both single-use and sterility symbols.
Labeling is linked to responsibility so that
when HCPs advise against the official labeling
they assume the responsibility for adverse out-
comes. Published injection technique recom-
mendations have usually opposed needle
reuse,83,92,189 for the reasons reviewed in
studies summarized in Supplemental Appen-
dix 8 (available online at http://www.
mayoclinicproceedings.org),190-193 but they.org/10.1016/j.mayocp.2016.06.010 1239
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1240stop short of declaring it seriously harmful to
the patient.
It seems that needle reuse, particularly
reuse frequency, is associated with the devel-
opment of LH. Local skin or SC tissue infec-
tions, injection pain, and unpleasantness
have not been clearly associated with limited
needle reuse (until needle blunting occurs).
The lack of infectious complications may be
attributed to the antimicrobial preservatives
in insulin preparations.
Recommendations.
d There is an association between needle reuse
and LH, although a causal relationship has
not been proved. There is also an association
between reuse and injection pain or
bleeding. Patients should be made aware of
these associations. A2
d Reusing insulin needles is not an optimal in-
jection practice, and patients should be
discouraged from doing so. Elsewhere in
these recommendations it is stated that
pen needles (and syringe needles) should
be used only once. They are no longer sterile
after use.3,4,83,84,88,109-111 A2
d However, patients who reuse needles should
not be subjected to alarming claims of
excessive morbidity from this practice. A3Bleeding and Bruising
Needles will occasionally hit a blood vessel or
a capillary bed, producing local bruising or
bleeding.194 Today’s needles are of much
smaller diameter than they once were, and
the amount of blood loss is usually inconse-
quential. Applying pressure to the site for 5
to 10 seconds should stop the bleeding. Vary-
ing the needle length does not alter the fre-
quency of bleeding or bruising.
Recommendations.
d Patients should be reassured that local
bruising and bleeding do not adversely
affect clinical outcomes or the absorption
of insulin. A2
d If bleeding and bruising are frequent or
excessive, the injection technique should
be carefully assessed as well as the presence
of a coagulopathy or the use of anticoagu-
lant or antiplatelet agents. A3Mayo Clin Proc. n September 2016;91Leakage of Insulin
There are3 types of leakage. Leaking from thepen
is due to a poor seal between the needle and the
cartridge in the pen. Dripping from the needle
(while it is on the pen) can occur when the
plunger is not held down correctly or the needle
is taken out of the skin too soon. Reflux or back-
flow out of the injection site can happen when
the needle is taken out too soon or for some
other reason (obese patient). Additional studies
on leakage are summarized in Supplemental
Appendix 9 (available online at http://www.
mayoclinicproceedings.org).195,196 Data on
innovations in needle geometry are available in
Supplemental Appendix 10 (available online at
http://www.mayoclinicproceedings.org).197-199
Recommendations: Leakage at Cartridge
and Pen Needle Connection.
d Ensure that the pen needle is ISO-certified
compatible with the insulin pen. A3
d Position the pen needle along the axis of the
pen before screwing or snapping it on. A3
d Pierce straight through the septum of the
cartridge. A3Recommendations: Dripping From the
Needle.
d Use needles that have a wider inner diameter
and improved insulin flow (eg, extra-thin-
walled needles).200,201 A1
d Count to 10 after the plunger is fully
depressed before removing the needle from
the skin to allow time for expulsive forces
to be transmitted through all pen parts to
the insulin column in the cartridge. A2
d By trial and error, patientsmay learn how long
they need to hold the button down and the
needle under the skin to avoid dripping
from the needle tip or backflow out of the
skin. This may be less than 10 seconds. A2
d Larger doses may be split to reduce the vol-
ume of insulin. A2
Recommendations: Skin Leakage.
d Use needles with thin-wall or extra-thin-wall
technology. A1
d Count to 10 after the plunger is fully
depressed before removing the needle from
the skin. This allows enough time for the
injected medication to spread out through(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
www.mayoclinicproceedings.org
NEW INSULIN DELIVERY RECOMMENDATIONSthe tissue planes and to cause the tissue to
expand and stretch. A2
d A small amount of skin leakage (a little pearl
of liquid at the injection site) can be ignored.
It is almost always clinically insignificant.
A1
d For patients who report frequent skin
leakage, direct observation of their self-
injection is important for detecting possible
technique-related issues that can be modi-
fied. A2PSYCHOLOGY
Beginning insulin therapy can be fraught with
psychological hurdles, regardless of the age of
the patient. Foremost among these is the fear
of pain. Insulin injections are usually not pain-
ful, except in the event that the needle hits a
nerve ending, which is quite infrequent. Never-
theless, some patients are quite sensitive to sen-
sations described as painful. Patient awareness
of injection discomfort has been studied exten-
sively and is related to 3 key factors: needle
length, needle diameter, and injection context.
Injection context includes the environment (eg,
noise and the presence of other people), the
appearance of the needle, and the anxieties of
the HCP and the family. The more apprehen-
sion the latter display, the greater the pain
and anxiety felt by the patient.202,203 This
reverse transference places a large responsibil-
ity on caregivers to assess their own attitudes
toward injection pain. Some patients note
discomfort when injecting insulins that have a
low pH. This seems, anecdotally, to be reported
more commonly in children. Other studies on
the psychology of insulin delivery are summa-




Emotional and Psychosocial Issues.
d Show empathy by addressing the patients’
emotional concerns first. The HCP should
explore worries and barriers to treatment
and acknowledge that anxiety is normal
when beginning any new medication, espe-
cially injection therapy. A2
d All patients, but especially adolescents, should
be encouraged to express their feelings aboutMayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orginjecting/infusing, particularly their anger,
frustration, or other struggles. A3
d Patients of all ages should be reassured that
this is a learning process and that the health
care team is there to help along the way. The
message is, “You are not alone, we are here
to help you; we will practice together until
you are comfortable giving yourself an injec-
tion.” A3
d With all patients, it is important to explain
that insulin is not a punishment or a failure.
Insulin is the best treatment we have for
managing blood glucose levels. For patients
with type 1 diabetes it is the primary treat-
ment, and for patients with type 2 diabetes
it is often an adjunct to oral therapy to
improve blood glucose control. For patients
with type 2 diabetes it is important that they
understand the natural progression of the
disease and that insulin therapy is a part of
the logical progression in its management
(Paul Hofman, MD, oral communication,
October 24, 2015).146,147,224-226 A3
d Patients should understand that improving
blood glucose control will make them feel
better. Many patients report an overall
improvement in their health and well-being
when taking insulin. The message is, “You
will not be urinating as frequently and
should sleep better. You will have more en-
ergy and improved vision. Managing blood
glucose with insulin will also help prevent
long-term complications.”147,227 A3
d Patients, especially adolescents, should be
given as much control as possible in
designing their regimen to fit their lifestyle.
This could include basal bolus therapy, car-
bohydrate counting, and using insulin pens
and insulin pumps. A3Strategies for Reducing Fear, Pain, and
Anxiety.
d Include caregivers and family members in
the planning and education of the patient,
and tailor the therapeutic regimen to the
individual needs of the patient. A3
d Have a compassionate and straightforward
approach when teaching injection tech-
nique. Demonstrate the injection technique
to the patient. Have the patient follow along
and then demonstrate correct technique
back to the educator or HCP. A3.org/10.1016/j.mayocp.2016.06.010 1241
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in case of anxiety provoked by seeing
sharps. Also consider using vibration, cold
temperature, or pressure to “distract” the
nerves (gate control theory) from the
perception of pain. A3
d Children have a lower threshold for pain.
The HCP should ask about pain (Paul Hof-
man, MD, oral communication, October
24, 2015).224 For young children, consider
distraction techniques or play therapy (such
as injecting a soft toy [stuffed animal or
doll]). Older children often respond better
to cognitive behavioral therapies,226 such as
guided imagery, relaxation training, active
behavioral rehearsal, graded exposure,
modeling, positive reinforcement, and incen-
tive scheduling. A2
d Fear and anxiety may be substantially
reduced by having the parent and child
give themselves a dry injection. Often they
are surprised and relieved at how painless
the injection is. A2
d Use of injection ports at the commencement
of therapy may help reduce anxiety and fear
of injections and its associated pain.227-230
B1
d Insulin pens with very short needles may be
more acceptable to patients than the syringe
and vial. This should be discussed with the
patient and family when teaching injection
therapy. The 4-mm pen needle is reported
by patients to be less painful than longer
needles.96,104,148,227 A2
d Patients who occasionally experience sharp
pain on injection should be reassured that
the needle may have touched a nerve
ending, which happens randomly and will
not cause any damage. If pain persists the
HCP should see the patient and evaluate
the injection technique. A3
d Keep insulin at room temperature for a more
comfortable injection. Injecting insulin
while it is still cold often produces more
pain. A3
d If bleeding or bruising occur, reassure the
patient that these do not affect the absorp-
tion of insulin or overall diabetes control.
If bruising continues or hematomas develop,
observe the injection technique and suggest
improvements (eg, better rotation of injec-
tion sites). A3Mayo Clin Proc. n September 2016;91Tips for Injection Education.
d Demonstrate proper injection technique to
the patient and family. Then have the pa-
tient and family demonstrate proper tech-
nique back to the HCP. A3
d Ensure that the skin is clean and dry before
injecting. Patients usually do not need to use
a disinfectant on the skin, but if they do,
they should allow it to dry completely
before injecting. A3
d Use needles of shorter length (4 mm or the
shortest available) and smaller diameter (high-
est gauge number), and the tip with the lowest
penetration force tominimize pain. Use a ster-
ile, new needle with each injection. A1
d Insert the needle through the skin in a smooth
but not jabbing movement. Pain fibers are in
the skin, and going through the skin too slowly
or too forcefully may increase the pain. A1
d Inject the insulin slowly, ensuring that the
plunger (on the syringe) or thumb button
(on the pen) has been fully depressed and
all the insulin has been injected. With pens,
the patient should count to 10 after the but-
ton has been depressed before withdrawing
the needle to get the complete dose. A3
d The HCP should teach the importance of
rotation and create a rotation pattern with
the patient when initiating injection therapy.
The message should be: “Insulin will not be
well-absorbed if it is always injected into the
same area. It is important to move injections
at least half an inch (1 cm) away from the
previous injection and to use all injection
sites on the body (back of the arms, but-
tocks, thighs, and abdomen).” A1
d If the same injection site is used repeatedly it
may become lumpy, firm, and enlarged. The
insulin will not work correctly if injected
into these areas. A1
d If pain is experienced when injecting large
volumes of insulin the dose may need to
be divided into 2 injections of smaller vol-
ume or the concentration of insulin may
need to be increased. A3TECHNOLOGY
1 Person/1 Pen
Sometimes macroscopic blood regurgitation
into a cartridge is observed. Should the(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
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could result in the transmission of blood-
borne diseases such as human immunodefi-
ciency virus or hepatitis. More concerning is
microscopic blood because the risk exists but
there is no visible clue. Even one injection
with an insulin pen can contaminate the insu-
lin cartridge with biologic, possibly infectious,
material. If the same cartridge is used to inject
another patient, transmission of this material
could occur, even if a new needle is used.
The implication is clear: there should never
be sharing of insulin pen cartridges between
patients. Additional studies on this risk are
summarized in Supplemental Appendix 12
(available online at http://www.mayoclinic
proceedings.org).231-234
Recommendations.
d Insulin pens, pen cartridges, and small indi-
vidual vials should not be shared to prevent
the transmission of infectious diseases. One
patient/1 insulin pen. A1
d Insulin pens, pen cartridges, and small indi-
vidual vials should be clearly labeled with
patient names/identifiers in health care
facilities where common storage is used,
eg, refrigerators. A2Insulin Infusion Sets for CSII
Continuous SC insulin infusion using an insu-
lin pump has been a treatment modality for
patients with diabetes, primarily those with
type 1, for more than 30 years.235 Insulin infu-
sion sets (IISs) are required to deliver insulin
into the SC tissue, but their role in CSII ther-
apy is often underappreciated by HCPs. As a
result, advances in IIS technology are stagnant
and overshadowed by the innovative advances
of insulin infusion pumps. There are, never-
theless, a large variety of IIS options available.
Complications related to IISs are common and
include infusion site, technical, and metabolic
manifestations; for these reasons, IISs are
considered the Achilles heel of CSII.236
In a randomized, open-label, pharmacoki-
netic study by McVey et al,237 irregularities in
insulin delivery during CSII were observed
when in-line pressure was used as an indicator
for flow. Significant increases in pressure dur-
ing infusion (which suggests flow interrup-
tions) were found over a 24-hour period inMayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.org20 adults with type 1 diabetes, often without
triggering the pump’s occlusion alarm. The
authors concluded that these silent, or suba-
larm, occlusions may potentially contribute
to unexplained hyperglycemia in patients
receiving CSII.
Hirsch238 reported the occurrence of silent
occlusions using insulin diluent in healthy vol-
unteers, in whom pressure measurements
were made. Silent occlusion was defined as a
continuous rise in pressure of at least 30 mi-
nutes without triggering the pump occlusion
alarm. These pressure-rise events occur
frequently during SC infusion (>35% of infu-
sions). Furthermore, these studies evaluated
the efficacy of a catheter with an additional
lumen on its side (known as a side-ported
catheter) for reducing flow interruptions or si-
lent occlusions. The use of a side-ported set
lowered the incidence of silent occlusions by
more than 75% compared with a conventional
Teflon IIS.239
Similar criteria for choosing needle length
for pen needles should apply to choosing
optimal IIS cannula length. Skin thickness
studies suggest that short cannula lengths are
appropriate to help reduce the risk of IM
insertion. Bolick240 conducted corollary imag-
ing studies using both fluoroscopy (in swine)
and magnetic resonance imaging (in human
volunteers) to characterize the IIS performance
during infusion and bolusing. The studies
provide visual evidence that IIS cannulas
measuring 9 mm or longer may increase the
risk of IM insertion, particularly in body areas
of reduced adipose tissue, such as the back of
the arm and the thigh. A summary of other
studies on the delivery issues surrounding
CSII is presented in Supplemental Appendix
13 (available online at http://www.mayoclinic
proceedings.org).161,241-244Recommendations.
d Population studies suggest that CSII can-
nulas should be changed every 48 to 72
hours with the goal of minimizing infusion
site adverse events and potential metabolic
deterioration. However, these times are pa-
tient dependent and should be adjusted
accordingly. A1
d All CSII users should be taught to rotate
infusion sites along the same principles.org/10.1016/j.mayocp.2016.06.010 1243
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jection sites. A1
d All CSII patients with unexplained glucose
variability, including frequent hypoglycemia/
hyperglycemia, should have infusion sites
checked for LH, nodules, scarring, inflamma-
tion, or other skin and SC conditions that
could affect insulin flow or absorption. A1
d All CSII patients should have their infusion
sites checked regularly (at least annually)
for LH by an HCP. A1
d If LH is suspected, the patient should be
instructed to stop infusing into these lesions
and to insert the catheter into healthy tissue.
A1
d Silent occlusion or interruption of insulin
flow should be suspected in any person
with unexplained glucose variability, unex-
plained hyperglycemia, or frequent hypogly-
cemia/hyperglycemia. B2
d If silent occlusion is suspected, CSII patients
should be considered for an alternative
catheter. A1
d All CSII patients should be considered for
the shortest needle/cannula available, along
the same principles as insulin injectors, to
minimize the risk of IM infusion. Young
children and very thin individuals may
need to insert into a lifted skinfold to avoid
IM insertion. B2
d The smallest-diameter needle/cannula should
be considered in CSII patients to reduce pain
and the occurrence of insertion failure. B2
d Angled IISs should be considered in CSII
patients who experience infusion site com-
plications with 90 IISs. B2
d All CSII patients who experience a hyper-
sensitivity reaction to cannula material or
adhesive should be considered for alterna-
tive options (alternative sets, tapes, or skin
barriers). A3
d CSII patients who are lean, muscular, or
active and have a high probability of the
cannula or tubing being dislodged may
benefit from angled (30-45) insertion of
their IIS.245 C3
d CSII patients who have difficulty inserting
their IIS manually for any reason should
insert it with the assistance of a mechanical
insertion device. C3
d CSII patients who become pregnant may
require adjustments to their IISs, infusionMayo Clin Proc. n September 2016;91site locations, and frequency of site changes.
B3Needlestick Injuries/Bloodborne Infection
Risk
Needles for delivering insulin are the most
commonly used sharps in the world. When
combined with lancet use for drawing blood,
the use of medical sharps by persons with
diabetes is far greater than that by any other
patient population. Most sharps use is in the
home setting by persons whose serostatus for
hepatitis, human immunodeficiency virus,
and other bloodborne pathogens is unknown.
Thus, needlestick injuries (NSIs) from diabetes
sharps are an important public health issue.
Technologies have emerged in recent years to
address the potential infection risk in this pop-
ulation, but they are not widely known or
used. A full summary of the literature
regarding NSI risk when delivering insulin is
presented in Supplemental Appendix 14
(available online at http://www.mayoclinic
proceedings.org).246-272
Recommendations.
d Safety-engineered devices play a critical
role in protecting injectors, pump users,
and downstream workers. Nurses and
other HCPs at risk must receive appro-
priate education and training in how to
minimize risk by following optimal tech-
niques, using safety devices, and wearing
appropriate protective clothing (eg,
gloves). A1
d Safety injection devices should be consid-
ered first-line choice if injections are given
by a third party. Pens and syringes with nee-
dles used in this setting should have protec-
tive mechanisms for all sharp ends of the
delivery device. A2
d The HCPs should be involved in the tria-
ling and choice of devices to be used in
their health care setting. Evaluation
before adoption should include key spe-
cialists (eg, infection control, occupa-
tional health, and experienced end
users).273,274 A1
d Health care settings where insulin pens are
used must follow a strict 1 patient/1 pen
policy. A2(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
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ported NSIs to determine whether they are
related to a device failure. A3
d To minimize the risk of NSI through a skin-
fold, the use of 4- and 5-mm pen needles or
6-mm insulin syringe needles without a
skinfold is recommended. If a lifted skinfold
is used, the patient should ensure that the
finger and thumb are approximately 1 inch
(25 mm) apart and should make the injec-
tion in the center of the fold, thus mini-
mizing through-skinfold NSI risk. A2
d Campaigns to increase NSI awareness should
be conducted regularly and should involve
all persons at potential risk for NSI. A1
d Needle recapping should not be done, and
HCPs should be especially trained to avoid
needle recapping. Manufacturers should
develop devices that automatically and
passively prevent needle recapping. A2
d Hospitals should encourage reporting of
NSIs and near misses and should establish
a blame-free culture. Review of all NSIs
and near misses should take place regularly
to assess educational needs and allow for
policy change. A1
d A review of adherence to guidelines and
appraisal of the effectiveness of education
and training should be performed at regular
intervals. A reporting system for violations
should exist. A2
d Proper use of safety devices is essential to
their effectiveness. When they are not acti-
vated, because of user forgetfulness, lack of
training, or inattention, they afford no addi-
tional risk reduction over nonsafety (con-
ventional) devices. A1
d Sharps containers should be easily accessible
at the point of care or beside the patient before
the injection or infusion. Containers should
bear the following or a similar warning: “Nee-
dles may seriously damage the health of
others. Please ensure their safe disposal.” A2
d Although hepatitis B virus vaccination
should be universal, at minimum it should
be offered by the employer to all workers
exposed to sharps. Vaccination status must
be reviewed every year at the employee’s
performance assessment.275 A1
d First aid information about what to do in the
event of an NSI should be readily available
in all health care facilities. A2Mayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orgd All workers in possible contact with sharps
should know the local safety and disposal
regulations. The societal and legal conse-
quences of not adhering should be
reviewed.276 A2
d Safe disposal of sharps should be taught to
patients and caregivers from the beginning
of injection or infusion therapy and rein-
forced throughout.277 A2
d Potential adverse events of NSIs should be
emphasized to the patient’s family, care-
givers, and service providers (eg, house-
keepers and trash collectors). A3
d Used sharps should never be discarded into
the public trash. A3DISCUSSION
In 2010, after the 2009 Third Injection Tech-
nique Workshop in Athens (TITAN), a compre-
hensive set of injection recommendations was
published.1 This document provided the stim-
ulus to many country-specific initiatives. The
Forum for Injection Technique (FIT), a commu-
nity of experienced diabetes specialist nurses
dedicated to best practice in injection technique,
began in the United Kingdom shortly after
TITAN and spawned many other FIT groups
throughout the world. As of 2016, there are
FIT boards in the United Kingdom, Ireland,
Canada, Dominican Republic, South Africa,
Korea, Norway, the Philippines, Taiwan,
Switzerland, and India.278,279
Similar initiatives in other countries (eg,
Turkey, Belgium, Italy, Germany, and China)
do not carry the FIT name but have led to
similar guidelines.280-285 These country ini-
tiatives play a critical role in establishing
best practice and in changing behavior for
countless patients and HCPs worldwide.
Such guidelines should be updated regularly.
Some countries (eg, Canada and the United
Kingdom) now publish their guidelines
only online to have more flexibility when
updating, increase ease of access, and save
on resources.
In these new recommendations we added
a variety of themes (eg, infusion, safety) and
covered all the key studies published since
TITAN. However, a variety of key injecting
parameters have not been studied in
sufficient depth and in specific populations.org/10.1016/j.mayocp.2016.06.010 1245
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rameters include injections during pregnancy,
injections using the newer analogues or GLP-1
receptor agonists, and injections in special
populations (eg, babies and the very elderly)
or under special conditions (eg, SC edema).
Investigators are encouraged to address these
issues through prospective, randomized clin-
ical trials.CONCLUSION
These evidence-based recommendations pro-
vide a new, practical, and comprehensive set
of guidelines for patients and professionals
worldwide. If followed, they should ensure
safe and efficacious delivery of diabetic thera-
pies into the SC space. To assist with imple-
mentation of these new recommendations,
we provide 6 sets of golden rules in the
Appendix. These rules are meant as a clear
and simple road map for nurses, educators,
and patients. If the rules are followed, nearly
all of the new recommendations will be
implemented.APPENDIX. SIX SETS OF GOLDEN RULES
TO ASSIST WITH IMPLEMENTATION OF THE
NEW RECOMMENDATIONS
Injection Technique in Adults
1. Insulin and glucagon-like peptide-1 recep-
tor agonists must be deposited into healthy
subcutaneous fat tissue, avoiding the intra-
dermal and IM spaces as well as scars and
LH.
2. 4-mm pen needles inserted at 90 are rec-
ommended for all adults regardless of age,
sex, ethnicity, or BMI. If patients need to
use needle lengths >4 mm or a syringe
(or where the presumed skin surface to
muscle distance is less than the needle
length), they must use a correctly lifted
skinfold to avoid IM injections.
3. Recommended sites for injection are the
abdomen, thigh, buttock, and upper arm:
a. Abdomen within the following bound-
aries: w1 cm above the symphysis pubis,
w1 cm below the lowest rib, w1 cm
away from the umbilicus, and laterally at
the flanksMayo Clin Proc. n September 2016;91b. Upper third anterior lateral aspect of
both thighs
c. Posterior lateral aspect of both upper
buttocks and flanks
d. Middle third posterior aspect of the up-
per arm
4. Detect and avoid injection into areas of
lipodystrophy.
5. Rotation of injection sites is critically
important and can be correctly performed
by:
a. Spacing injections within a site approxi-
mately 1 fingerbreadth apart
b. Using a single injection site no more
frequently than every 4 wk.Injection Technique in Children
1. Insulin must be deposited into healthy sub-
cutaneous fat tissue, avoiding the intrader-
mal and IM spaces as well as scars and LH.
2. Injection should avoid bony prominences
by 1 to 2 adult fingerbreadths. Preferred
sites are:
a. Abdomen, 2 adult fingerbreadths away
from the umbilicus
b. Upper third anterior lateral aspect of
both thighs
c. Posterior lateral aspect of both upper
buttocks and flanks
d. Middle third posterior aspect of the up-
per arm
3. Consideration should be given to the type
of insulin and the time of day when select-
ing injection sites.
4. Correct rotation of injection sites must be
followed at all times to prevent LH. 4-mm
pen needles should be used for all children
and young adults regardless of age, sex,
ethnicity, or BMI.
5. Children and young adults are at risk for
accidental IM injection. A 2-finger lifted
skinfold usually prevents IM injection but
is much less effective in the thigh than in
the abdomen. Lean children should use a
lifted skinfold when the presumed skin sur-
face to muscle distance is less than the nee-
dle length plus 3 mm.(9):1231-1255 n http://dx.doi.org/10.1016/j.mayocp.2016.06.010
www.mayoclinicproceedings.org
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1. All patients who inject or infuse insulin
must have their sites checked at every reg-
ular visit, or at least every year:
a. HCPs in diabetes must be trained to
correctly screen for LH and other site
complications.
b. All persons who self-inject/infuse insulin
or other injectables must be taught to
self-inspect sites and be able to distinguish
healthy from unhealthy tissue.
2. Clinicians must monitor and record the
evolution of LH, possibly using photog-
raphy (with the patient’s consent); body
maps with descriptors for size, shape, and
texture; or transparent graduated recording
sheets.
3. With patient consent, clinicians should
mark the border of all LH and other site
complications with skin-safe single-use
markers and instruct patients to avoid using
marked areas until instructed otherwise.
4. Patients with LH who have been instructed
to stop injecting/infusing into affected
tissue must be:
a. Allowed to experience the actual meta-
bolic difference it makes to use normal
tissue instead of LH (this is a key to
long-term adherence)
b. Informed that somemild painmay be expe-
rienced when injecting into normal tissue
c. Supported by an HCP to monitor
glucose levels frequently due to the risk
of unexpected hypoglycemia
d. Assisted in the reduction of their insulin
doses in line with glucose results, knowing
that reductions often exceed 20% of their
original dose
e. Optimized to 4-mm pen needles/6-mm
insulin syringes or the shortest needle
length available to minimize accidental
IM risk due to using larger zones
f. Optimized to advanced needle geometry,
including thin-walled and extra-thin-walled
needles (if available) to minimize pain and
discomfort and to maximize ease of dosing
when injecting into healthy tissue
5. All patients must be supported to correctly
rotate injection/infusion sites and cautionedMayo Clin Proc. n September 2016;91(9):1231-1255 n http://dx.doi
www.mayoclinicproceedings.orgabout the risks of reusing needles to mini-
mize risk of injection site complications.
a. Principles of correct rotation technique
must be taught to patients, and rotation
technique must be assessed at least every
year and more frequently if required.
b. Correct rotation ensures that injections
are spaced out approximately 1 cm (a fin-
gerbreadth) from each other and that a
single injection site is used no more
frequently than every 4 wk.
Psychological Issues Regarding Insulin
Delivery
1. All patients and caregivers should be offered
general and individualized education/
counseling that will facilitate optimal care.
2. Ensure that all patients and caregivers are
supported by their HCP using patient-
centered evidence-based psychological
educational tools and strategies to achieve
mutually agreed goals.
3. Diabetes care HCPs should be skilled in
identifying psychological issues that impact
insulin delivery.
4. HCPs must have a range of therapeutic
behavioral skills to minimize the psycho-
logical distress and the impact of insulin
therapy.
5. Various methods of minimizing pain and
fear of injection should be used to reduce
the psychological impact.
Needlestick Injuries and Sharps Disposal
1. All HCPs, employers, and employees must
comply with relevant international, national,
and local legislation for the use of sharps.
2. Sharp medical devices present a potential
risk of injury and transmission of disease.
All HCPs, employers, and employees must
ensure the safest possible working environ-
ment by:
a. Conducting regular risk assessment and
providing continuing education and training
b. Providing and using a means of safe
disposal of used sharps
c. Prohibiting needle recapping
d. Encouraging reporting of incidents.org/10.1016/j.mayocp.2016.06.010 1247
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all HCPs and by all third-party caregivers
using sharps (eg, injections, blood testing,
infusion) in all hospitals, clinics, and other
institutions, such as schools and prisons.
Best practice for pen needles requires that
both ends of the needle be protected.
4. Safe disposal requires that:
a. Correct disposal procedures and personal
responsibility be taught topatients and care-
givers by the dispensing clinician (including
pharmacists) and be regularly reinforced
b. Safe sharps disposal systems and pro-
cesses be present and known to all per-
sons at risk for sharps contact
c. Environments where others are at risk (eg,
care homes, schools, and prisons or around
rubbish workers and cleaners) be provided
safety education and safety devices
d. Patients diagnosed as having bloodborne
diseases such as human immunodeficiency
virus and hepatitis be supported to use
safety-engineered devices and dispose of
them safely
e. Sharps never be placed directly in public
or household trash
Insulin Infusion
1. Insulin infusion cannula must be inserted
into healthy subcutaneous fat tissue, avoiding
underlyingmuscle as well as areas of skin irri-
tation, scarring, LH, and lipoatrophy.
2. If bleeding or significant pain occurs on
insertion, the set should be removed and
replaced.
3. Preferred sites for infusion cannula should
be individualized but include:
a. Abdomen, avoiding bony prominences
and the umbilicus
b. Upper third anterior lateral aspect of
both thighs
c. Posterior lateral aspect of both upper
buttocks and flanks
d. Middle third posterior aspect of upper arm
4. Infusion cannula sites should be rotated to
avoid complications. This usually involves
moving to a new location. In-site duration
should be individualized but typically
should not be more than 72 hours.Mayo Clin Proc. n September 2016;915. If kinking occurs, consider a shorter can-
nula or an oblique or steel set. If frequent
silent occlusions or unexplained hypergly-
cemia occur, consider using a different
type of infusion set, including a cannula
with a side port, if available.
BMI ¼ body mass index; HCP ¼ health
care professional; IM ¼ intramuscular; LH ¼
lipohypertrophy.SUPPLEMENTAL ONLINE MATERIAL
Supplemental material can be found online at
http://www.mayoclinicproceedings.org. Sup-
plemental material attached to journal arti-
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